Where the money sits
Our starting point is simple. Large academic publishers are profitable businesses. RELX, Springer Nature and Wiley operate with high margins and rely on subscription fees, institutional contracts and article processing charges. These revenue streams reward volume and prestige. When a highly cited paper is questioned a retraction can damage journal metrics and future income. I follow company filings and annual reports to see that the financial incentive is to preserve perceived value. See the RELX investor pages and independent reporting for profit estimates.
Pay to publish and the perverse logic
Article processing charges for open access mean authors or funders pay to publish. That model shifts incentives. I have found that APC income creates pressure to accept and retain papers. The more articles processed the more revenue. Investigative journalists such as Ivan Oransky and Adam Marcus at Retraction Watch have documented how retraction decisions can be slow and inconsistent. I credit those records as a running ledger of cases where financial logic appears to matter.
Industry funding and conflicts of interest
Beyond publishers there are funders and corporate sponsors. Pharmaceutical and biotech companies fund research and sometimes pay authors directly. Public records, such as the US Open Payments database, show payments that create potential conflicts. Journal editors face difficult choices when a paper with industry links is challenged. I note this is about suggestion of influence rather than proof. Katherine Eban and others have documented cases where funding shaped research narratives. I cite those investigations when they reveal financial ties.
Lobbying, think tanks and donor networks
Publishers and scholarly societies lobby governments on copyright and open access rules. Lobby registers and lobbying expenditure data on OpenSecrets show the flow of influence. Foundations and wealthy donors also shape research agendas through grants to labs and think tanks. I trace donations and grants in charity registers to reveal how interests line up behind certain outcomes. Again this suggests influence on the ecosystem but does not prove direct editorial control of individual retractions.
Why retractions are delayed
When problems emerge journals can opt for corrections, expressions of concern or silence. Each choice has reputational and financial consequences. Our team has seen patterns where politically sensitive or commercially valuable papers attract prolonged debate rather than swift retraction. Retraction Watch and academic studies such as Fang, Steen and Casadevall in PNAS show that misconduct explains many retractions, yet the handling varies by publisher. I point to those analyses as evidence of systemic unevenness.
What we can do and what I recommend
I believe the remedy starts with transparency. Public registers of reviewer payments, clearer disclosure of APC revenues and stronger independence for editorial boards would reduce perverse incentives. Regulators should also scrutinise lobbying by publishers and donors which can shape policy on retractions and open access. I use public filings, charity registers and investigative reports to map these links and to show where reforms would hit the right targets. This mapping suggests influence rather than proving a single conspiratorial script.
References and sources
- Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. PNAS 2012.
- Retraction Watch database and reporting. Ivan Oransky, Adam Marcus.
- RELX Group investor and annual reports.
- OpenSecrets lobbying and expenditure records.
- US Open Payments database for industry payments to clinicians and researchers.
- Brian Deer reporting on conflicts and the Wakefield case, BMJ.
- The Guardian coverage on academic publishing profits.
Sign up to our newsletter for daily briefs.